Search research articles
Contact Us
Filters
Showing results (91-100 of 126) with videos related to
Page
of 13
Sort By:
Lancet (London, England)
|
December 18, 2015
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
Martin Dreyling, Wojciech Jurczak, Mats Jerkeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2019
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
John P Leonard, Marek Trneny, Koji Izutsu, et al.
Ejhaem
|
November 29, 2023
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial
Paul G Richardson, Thierry Facon, Christopher P Venner, et al.
Blood
|
March 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Thierry Facon, Christopher P Venner, Nizar J Bahlis, et al.
Haematologica
|
March 5, 2026
Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial
Pau Abrisqueta, Yasmin H Karimi, Daniel Morillo, et al.
Cancer Immunology Research
|
June 14, 2024
Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion
Stijn De Munter, Juliane L Buhl, Laurenz De Cock, et al.
The Journal of Experimental Medicine
|
August 18, 2021
Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice
Tim Pieters, Sara T'Sas, Stijn Vanhee, et al.
Haematologica
|
March 4, 2021
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study
Cyrille Hulin, Fritz Offner, Philippe Moreau, et al.
Intensive Care Medicine
|
September 19, 2024
Publisher Correction: Coaching doctors to improve ethical decision-making in adult hospitalized patients potentially receiving excessive treatment. The CODE stepped-wedge cluster randomized controlled trial
Dominique D Benoit, Aglaja De Pauw, Celine Jacobs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
Michael Crump, Sirpa Leppä, Luis Fayad, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 126) with videos related to
Sort By:
Page
of 13
Lancet (London, England)
|
December 18, 2015
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
Martin Dreyling, Wojciech Jurczak, Mats Jerkeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2019
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
John P Leonard, Marek Trneny, Koji Izutsu, et al.
Ejhaem
|
November 29, 2023
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial
Paul G Richardson, Thierry Facon, Christopher P Venner, et al.
Blood
|
March 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Thierry Facon, Christopher P Venner, Nizar J Bahlis, et al.
Haematologica
|
March 5, 2026
Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial
Pau Abrisqueta, Yasmin H Karimi, Daniel Morillo, et al.
Cancer Immunology Research
|
June 14, 2024
Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion
Stijn De Munter, Juliane L Buhl, Laurenz De Cock, et al.
The Journal of Experimental Medicine
|
August 18, 2021
Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice
Tim Pieters, Sara T'Sas, Stijn Vanhee, et al.
Haematologica
|
March 4, 2021
Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study
Cyrille Hulin, Fritz Offner, Philippe Moreau, et al.
Intensive Care Medicine
|
September 19, 2024
Publisher Correction: Coaching doctors to improve ethical decision-making in adult hospitalized patients potentially receiving excessive treatment. The CODE stepped-wedge cluster randomized controlled trial
Dominique D Benoit, Aglaja De Pauw, Celine Jacobs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2016
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
Michael Crump, Sirpa Leppä, Luis Fayad, et al.
Page
of 13